FDA Gives Compounded Tirzepatide 90 Days to Disappear — What Patients Need to Know Now (2026)

The FDA has issued definitive new guidelines requiring all compounding, distribution, or dispensing of compounded tirzepatide injections to cease within 90 days, marking the most aggressive enforcement action yet against compounded GLP-1 drugs since the official shortage ended. Patients currently using compounded tirzepatide products must transition to FDA-approved alternatives like Mounjaro within the next three months or face potential supply disruption.

This enforcement deadline represents a watershed moment in the GLP-1 industry. For nearly two years, compounded versions of tirzepatide (the active ingredient in Mounjaro and Zepbound) have filled a critical access gap for patients unable to afford brand-name medications. Now, with the shortage officially declared over, the FDA is moving decisively to eliminate these unregulated products from the market.

Understanding the FDA's 90-Day Deadline

The new FDA guidance establishes a firm timeline: all compounded tirzepatide products must cease production and distribution within 90 days from the date of announcement. This applies to compounding pharmacies, telehealth platforms, and any other entities producing unapproved versions of the medication.

The enforcement mechanism includes potential DOJ referrals for non-compliant pharmacies, making this far more than a symbolic gesture. Industry experts note that the FDA appears committed to closing the chapter on compounded GLP-1s that began during the supply crisis of 2023-2024.

For patients, this means the next three months represent a critical window to make alternative arrangements. Those who continue using compounded products after the deadline risk losing access entirely, with no clear pathway to continued supply.

What This Means for Current Compounded Tirzepatide Users

If you're currently taking compounded tirzepatide, you have several options to consider in the coming weeks. The most straightforward path is transitioning to FDA-approved Mounjaro or Zepbound, depending on whether you're using the medication for diabetes or weight loss. However, these brand-name options come with significant cost considerations.

For patients who have been relying on compounded versions due to cost barriers, the situation presents a genuine challenge. Brand-name tirzepatide can cost $1,000-$1,350 per month without insurance, placing it out of reach for many patients. However, there are alternatives worth exploring.

Remedy Meds can help connect patients with licensed providers offering FDA-approved GLP-1 options at more affordable price points. Additionally, the newly launched TrumpRx platform offers potential discounts for qualifying patients, and some telehealth providers offer payment plans or savings programs that may make brand-name medication more accessible.

The End of the GLP-1 Shortage Era

This enforcement action effectively marks the official end of the GLP-1 shortage era that began in early 2023. During that period, demand for Ozempic, Wegovy, Mounjaro, and Zepbound dramatically outstripped supply, creating an opening for compounders to produce unapproved versions of these medications.

Novo Nordisk and Eli Lilly have spent billions expanding manufacturing capacity over the past two years, and the FDA's determination that the shortage has ended reflects this increased supply. However, many patients grew accustomed to using compounded versions and may not have considered the eventual transition back to FDA-approved products.

The 90-day timeline gives both patients and providers a clear deadline for making this transition. Healthcare providers are urged to begin conversations with patients now about their options, rather than waiting until the last minute when supply chains may become strained.

Impact on Compounding Pharmacies and Telehealth

The FDA's decision will have significant ripple effects throughout the telehealth and compounding pharmacy industries. Companies that have built substantial businesses around compounded GLP-1s will need to pivot or wind down those operations.

Some telehealth platforms have already begun transitioning patients to FDA-approved medications or exploring other revenue streams. The recent removal of semaglutide products from Hims & Hers following FDA warnings prefigured this broader shift.

Compounding pharmacies that specialized in GLP-1 production may face difficult business decisions in the coming months. While some may attempt to shift focus to other medications, the financial impact of losing tirzepatide revenue could force consolidation or closure in this sector.

Looking Ahead: Patient Options

As the 90-day deadline approaches, patients should take proactive steps to ensure continuity of care. Here are the primary options available:

Transition to FDA-approved tirzepatide: Mounjaro (for diabetes) and Zepbound (for weight loss) remain the gold standard. Check with your insurance provider about coverage options and consider manufacturer savings programs.

Explore alternative GLP-1 medications: Semaglutide (Ozempic/Wegovy) offers similar benefits and may be more readily available. Your healthcare provider can help determine if switching makes sense for your situation.

Investigate patient assistance programs: Both Novo Nordisk and Eli Lilly offer patient assistance programs for qualifying individuals who cannot afford medication costs.

Consider telehealth alternatives: Licensed telehealth providers can offer consultations and prescriptions for FDA-approved GLP-1 medications, often at competitive prices.

FAQ

When exactly does the 90-day deadline expire?

The FDA's guidance establishes a 90-day window from the date of announcement. Patients should plan to transition to FDA-approved alternatives before this deadline to avoid supply disruption.

Will I be able to find compounded tirzepatide after the deadline?

The FDA's enforcement action makes continued distribution illegal after the 90-day period. Patients should not rely on finding compounded products after the deadline.

What if I can't afford brand-name Mounjaro or Zepbound?

Several options exist: manufacturer patient assistance programs, the TrumpRx discount platform, and telehealth providers offering competitive pricing. Remedy Meds can connect you with options that may be more affordable than retail prices.

Don't wait until the last minute. Contact a licensed healthcare provider now to discuss your transition options and ensure continuous access to GLP-1 therapy.